US 12,295,976 B2
Personalized cancer vaccines
Christopher Larson, San Diego, CA (US); Bryan T. Oronsky, Los Altos Hills, CA (US); and Tony R. Reid, San Diego, CA (US)
Assigned to EPICENTRX, INC., La Jolla, CA (US)
Appl. No. 17/042,822
Filed by EpicentRx, Inc., La Jolla, CA (US)
PCT Filed Mar. 28, 2019, PCT No. PCT/US2019/024684
§ 371(c)(1), (2) Date Sep. 28, 2020,
PCT Pub. No. WO2019/191494, PCT Pub. Date Oct. 3, 2019.
Claims priority of provisional application 62/649,206, filed on Mar. 28, 2018.
Prior Publication US 2021/0015878 A1, Jan. 21, 2021
Int. Cl. A61K 35/761 (2015.01); A61K 38/16 (2006.01); C12N 15/10 (2006.01); C12N 15/861 (2006.01)
CPC A61K 35/761 (2013.01) [A61K 38/16 (2013.01); C12N 15/102 (2013.01); C12N 15/861 (2013.01)] 19 Claims
 
1. A method for producing a personalized recombinant adenovirus for a subject in need thereof, comprising the steps of:
1) sequencing DNA or RNA in a sample obtained from the subject to identify one or more mutations resulting in one or more cancer antigen specific to the subject,
2) producing one or more transgenes, wherein each of the transgenes comprises one or more mutations identified in step (1), and wherein the one or more mutations are encoded by mutant nucleotide sequences that are separated by a peptide linker, an internal ribosome entry site (IRES), a ribosome skipping sequence, or a combination thereof; and
3) inserting the one or more transgenes in step (2) into the genome of a recombinant adenovirus to produce the personalized recombinant adenovirus, wherein transcription of the transgenes is active in cancer cells and/or hyperproliferative cells, but is attenuated in normal cells.